Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate

Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for autoimmune, ...

Hidden molecular switch controls taste, metabolism and gut function

Northwestern University scientists have uncovered a hidden molecular "control switch" inside a protein that helps the body ...
Nasdaq

InnoCare Wins NMPA Approval Of Phase II Trial Of ICP-488 In Cutaneous Lupus Erythematosus

(RTTNews) - InnoCare Pharma (INCPF) today announced that China's National Medical Products Administration has approved its IND application to initiate Phase II clinical trial of ICP-488, a novel TYK2 ...
BioSpace

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today ...
Cancer Research

AstraZeneca Jumps on Pan-KRAS Inhibitor

UK–based pharmaceutical giant AstraZeneca will acquire the rights to Jacobio Pharma’s JAB-23E73 outside of China for an upfront payment of $100 million and up to an additional $1.915 billion if the ...
Morningstar

Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73

BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73 ...